IRIDEX CORP — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
IRIDEX reported Q2 2026 total revenue of $12.6M (down 7% YoY from $13.6M). Cyclo G6 glaucoma probes grew 35% in volume to 17,700 units, driving 19% product family revenue growth to $3.9M; however, retina revenue fell 19% to $6.5M due to Middle East disruptions and China sell-through weakness. The company posted a net loss of $1.3M ($0.07/share) and achieved positive operating cash flow. Cash position declined to $4.7M from $6.0M at year-start. Full-year 2026 revenue guidance reaffirmed at $51–53M.
Why this rating
Mixed Q2 results with offsetting trends (glaucoma growth vs. retina decline). Cash burn and declining cash balance are concerning for a $14.2M market-cap company; however, positive operating cash flow and cost-control initiatives provide some mitigation. Not transformational but reflects execution risk.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.